期刊文献+

谷氨酸受体基因多态性与精神分裂症的相关性研究 被引量:4

Association study of schizophrenia and glutamic acid receptor gene polymorphism
原文传递
导出
摘要 目的探讨谷氨酸受体基因(GRIK2)多态性与精神分裂症的相关性。方法运用聚合酶链反应扩增及单核苷酸多态性的分子生物学技术,收集符合精神分裂症诊断标准的98个先证者及其父母组成的核心家系,对其谷氨酸受体基因rs1338165,rs728024,rs1408768,rs1335042多态性分型,进行精神分裂症的谷氨酸受体基因多态性的关联分析和传递不平衡(TDT)检验。结果rs1335042等位基因与精神分裂症相关联(P=0.026261),其中等位基因A是保护因素(Z=-2.222),G为危险因素(Z=2.222);rs1408768、rs728024、rs1338165与精神分裂症无关联。结论谷氨酸受体基因rs1335042与精神分裂症相关联。 Objective To detect the genetic association between schizophrenia and rs1338165,rs728024, rs1408768,rs1335042 polymorphism at nucleotide of the glutamic acid receptor gene. Methods Observed in a sample of 98 parent/offspring trios where the proband net the American classification and diagnostic criteria for mental disorders. The Forth Revised Edition, criteria for schizophrenia using transmission/disequilibrium test (TDT) analysis. The polymorphism of glutamic acid receptor gene was detected with PCR methods and SNP typing in all nucleus families. Results The rs1335042 allele is connected with schizophrenia (P= 0. 026261 ). Allele A was protective factor ( Z = -2. 222) and allele G was hazard factor ( Z = 2. 222 ). The rs1408768, rs728024 and rs1338165 allele was independence with schizophrenia. Conclusion It shows an association between schizophrenia and the rs1335042 polymorphism at nucleotide of glutamic acid receptor gene in Chinese.
出处 《中华行为医学与脑科学杂志》 CAS CSCD 北大核心 2009年第12期1093-1096,共4页 Chinese Journal of Behavioral Medicine and Brain Science
基金 陕西省卫生厅基金(06034)
关键词 精神分裂症 谷氨酸受体基因 多态性 关联分析 Schizophrenia Glutamie acid receptor genetics Polymovphism Association analysis
  • 相关文献

同被引文献59

  • 1汪作为,方贻儒,江三多.精神分裂症谷氨酸假说的分子生物学研究进展[J].上海精神医学,2005,17(1):56-58. 被引量:4
  • 2汪作为,刘人申,张少平,周天骍,陈银娣,方贻儒,江三多.精神分裂症及攻击行为与离子型谷氨酸受体-6基因多态性关联研究[J].中国行为医学科学,2006,15(2):104-106. 被引量:17
  • 3Motlova L, Spaniel F, Hoschl C, et al. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders? Ann Clin Psychiatry,2007,19: 133-143,.
  • 4Hashimoto K,Sudo T, Hirano M,et al. Efficacy and safety of zotepine for patients with treatment-resistant schizophrenia. Sehizophr Res, 2006,87 : 332-333.
  • 5Lin CH, Chou LS,Lin CH, et al. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry ,2007,68 : 1522-1527.
  • 6Nakamura S,Ago Y,hoh S,et al. Effect of zotepine on dopamlne,serotonin and noradrenaline release in rat prefrontal cortex. Eur J Pharmacol,2005 ,528 :95-98,.
  • 7Kuhota T, Jibiki I, Ishikawa A, et al. Increase in extracellular dopamine levels during clozapine-induced potentiation in the hippocampal dentate gyrus of chronically prepared rabbits. Can J Physiol Pharmacol, 2008,86:249-256.
  • 8Shoho M, Kondo Y, Yamada H, et al. Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmaeol Exp Ther,2010,333:772-781.
  • 9Amann B,Sterr A, Mergl R, et al. Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disord, 2005,7 : 471- 476.
  • 10Kubota T,Jibiki I,Enokido.F,et al. Effects of MK-801 on clozapine- induced potentitation of excitatory synaptic response in the perforant path-dentate gyrus pathway in chronically prepared rabbits. Eur J Pharmacol, 2000,395 : 37 -42.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部